US2022289660A1PendingUtilityA1

Compounds and methods for delivery of prostacyclin analogs

84
Assignee: UNITED THERAPEUTICS CORPPriority: May 22, 2003Filed: Apr 4, 2022Published: Sep 15, 2022
Est. expiryMay 22, 2023(expired)· nominal 20-yr term from priority
Inventors:Ken Phares
A61K 31/192C07C 229/08A61P 43/00A61K 31/557C07F 9/117C07F 9/091A61P 9/00A61K 9/0053C07C 2603/10A61K 31/223C07C 59/70C07C 51/412C07C 235/06A61P 17/00A61K 31/19A61K 31/235A61K 9/0019A61P 29/00C07C 259/06A61P 11/00A61P 25/00A61K 31/216C07C 235/08A61P 9/10A61P 9/12C07C 69/712A61P 15/00A61P 9/04A61P 7/02A61P 9/08A61P 9/14A61P 35/00A61P 27/02A61P 17/06C07C 405/00A61P 13/12C07C 59/13
84
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing

Claims

exact text as granted — not AI-modified
1 .- 12 . (canceled) 
     
     
         13 . A pharmaceutical composition comprising a) an effective amount of treprostinil or a pharmaceutically acceptable salt or ester thereof and b) polysorbate 80. 
     
     
         14 . The pharmaceutical composition of  claim 13 , wherein the pharmaceutical composition is in the form of a powder. 
     
     
         15 . The pharmaceutical composition of  claim 14 , wherein the pharmaceutical composition further comprises a buffer. 
     
     
         16 . The pharmaceutical composition of  claim 13 , wherein the pharmaceutical composition further comprises a buffer. 
     
     
         17 . The pharmaceutical composition of  claim 13 , wherein the pharmaceutical composition comprises a) a pharmaceutically acceptable salt of treprostinil and b) polysorbate 80. 
     
     
         18 . The pharmaceutical composition of  claim 17 , wherein the pharmaceutically acceptable salt is treprostinil sodium. 
     
     
         19 . The pharmaceutical composition of  claim 18 , wherein the pharmaceutical composition is in the form of a powder. 
     
     
         20 . The pharmaceutical composition of  claim 17 , wherein the pharmaceutical composition is in the form of a powder. 
     
     
         21 . The pharmaceutical composition of  claim 17 , wherein the pharmaceutical composition further comprises a buffer. 
     
     
         22 . The pharmaceutical composition of  claim 18 , wherein the pharmaceutical composition further comprises a buffer. 
     
     
         23 . The pharmaceutical composition of  claim 19 , wherein the pharmaceutical composition further comprises a buffer. 
     
     
         24 . The pharmaceutical composition of  claim 20 , wherein the pharmaceutical composition further comprises a buffer.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.